The Schizophrenia Drugs Market is entering a revitalization phase, fueled by new mechanisms of action, long-acting injectables (LAIs), and industry acquisitions that signal renewed interest. The convergence of clinical need, evolving regulation, and advanced pipelines is helping reshape therapeutic options for schizophrenia. The global schizophrenia drugs market size was valued at USD 7.84...